ArticleInflammatory bowel diseases2022

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.

María Chaparro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.